In a parallel analysis of DOCK4 levels within the AZURE trial, patients’ high DOCK4 expression correlated with the risk of bone metastasis (HR 2.13, 95%CI 1.06–4.30, p = 0.034) [22]. The gene discussed is DOCK4; the disease is bone metastasis.